Hormonal
Lifestyle interventions (caloric restriction and exercise) alone are ineffective for long-term obesity treatment because they trigger potent homeostatic adaptive responses (metabolic, hormonal, and appetitive) that defend a higher adipose mass set point and inevitably lead to weight regain.
Stop relying on willpower and calorie counting alone to cure obesity. Your body is biologically fighting to keep its weight at a higher 'set point' through hunger hormones and slowed metabolism. This is not your fault. To achieve lasting weight loss, you likely need medical or surgical interventions that override these biological defenses, as lifestyle changes alone will eventually trigger a rebound effect.
To date, no amount of weight loss duration through lifestyle (dieting and exercise) interventions alone has been shown to 'reset' the homeostatically defended adipose mass to a lower level [10]. The inevitable adipose mass regain... is instead indicative of the chronic (sometimes progressive) nature of the disease of obesity necessitating lifelong therapies.
Why this rating
Based on a comprehensive review of multiple studies and physiological principles cited in the text.
Source
Metabolic and appetitive regulation of adipocyte mass during treatment of obesity
Jonathan Q. Purnell et al. · Journal of Internal Medicine · 2025
DOI 10.1111/joim.70045
More from this paper
- Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.Good
- Metabolic adaptation during weight loss involves a 15-20% reduction in daily energy expenditure beyond what is expected from mass loss, which persists until the previous weight is regained.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →